Table 1.
Characteristics and Medications of the Study Patients at Baseline
| Variable | |
|---|---|
| n (male/female) | 9 (7/2) |
| Age, years | 71 ± 14 |
| eGFR, mL/min/1.73 m2 | 45.2 ± 6.2 |
| UACR, mg/g Cr | 191 (68–2255) |
| HbA1c, % | 6.7 ± 0.6 |
| Medications | |
| Antidiabetic agents, n (%) | |
| DPP-4 inhibitors | 6 (66.7) |
| Insulin | 2 (22.2) |
| α-Glucosidase inhibitors | 1 (11.1) |
| Metformin | 0 (0) |
| Sulfonylurea | 0 (0) |
| Antihypertensive agents, n (%) | |
| Angiotensin II receptor blockers | 9 (100) |
| ACE inhibitors | 0 (0) |
| Mineralocorticoid receptor antagonist | 0 (0) |
| Calcium channel blockers | 7 (77.8) |
| Diuretics | 1 (11.1) |
| α-Blockers | 2 (22.2) |
| β-Blockers | 2 (22.2) |
| Antihyperuricemic agents, n (%) | 5 (55.6) |
| Statins, n (%) | 5 (55.6) |
Data are expressed as mean ± standard deviation or median (interquartile range).
ACE, angiotensin converting enzyme; Cr, creatinine; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; UACR, urinary albumin-to-creatinine ratio.